These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23651402)

  • 1. Effects of nanosuspension formulations on transport, pharmacokinetics, in vivo targeting and efficacy for poorly water-soluble drugs.
    Wang Y; Miao X; Sun L; Song J; Bi C; Yang X; Zheng Y
    Curr Pharm Des; 2014; 20(3):454-73. PubMed ID: 23651402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies.
    Zhang X; Li LC; Mao S
    Curr Pharm Des; 2014; 20(3):388-407. PubMed ID: 23651400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical method for preparing nanosuspension formulations for toxicology studies in the discovery stage: formulation optimization and in vitro/in vivo evaluation of nanosized poorly water-soluble compounds.
    Komasaka T; Fujimura H; Tagawa T; Sugiyama A; Kitano Y
    Chem Pharm Bull (Tokyo); 2014; 62(11):1073-82. PubMed ID: 25366311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies.
    Du J; Li X; Zhao H; Zhou Y; Wang L; Tian S; Wang Y
    Int J Pharm; 2015 Nov; 495(2):738-49. PubMed ID: 26383838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
    Chavhan SS; Petkar KC; Sawant KK
    Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation aspects of intravenous nanosuspensions.
    Patel D; Zode SS; Bansal AK
    Int J Pharm; 2020 Aug; 586():119555. PubMed ID: 32562654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
    Leone F; Cavalli R
    Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
    Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
    Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
    Kayaert P; Li B; Jimidar I; Rombaut P; Ahssini F; Van den Mooter G
    Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucus-Penetrating Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal Surfaces.
    Yu T; Chisholm J; Choi WJ; Anonuevo A; Pulicare S; Zhong W; Chen M; Fridley C; Lai SK; Ensign LM; Suk JS; Hanes J
    Adv Healthc Mater; 2016 Nov; 5(21):2745-2750. PubMed ID: 27717163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of an orodispersible film containing drug nanoparticles.
    Shen BD; Shen CY; Yuan XD; Bai JX; Lv QY; Xu H; Dai L; Yu C; Han J; Yuan HL
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1348-56. PubMed ID: 24103635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanosuspensions in drug delivery.
    Rabinow BE
    Nat Rev Drug Discov; 2004 Sep; 3(9):785-96. PubMed ID: 15340388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
    Merisko-Liversidge E; Liversidge GG
    Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of nanosuspensions in drug delivery.
    Wang Y; Zheng Y; Zhang L; Wang Q; Zhang D
    J Control Release; 2013 Dec; 172(3):1126-41. PubMed ID: 23954372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery.
    Brough C; Williams RO
    Int J Pharm; 2013 Aug; 453(1):157-66. PubMed ID: 23751341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1501-19. PubMed ID: 21919807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.
    Agarwal V; Bajpai M
    Recent Pat Nanotechnol; 2015; 9(3):178-94. PubMed ID: 27009133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a screening platform for the formulation of poorly water-soluble drugs as albumin-stabilized nanosuspensions using nab™ technology.
    Adick A; Hoheisel W; Schneid S; Hester S; Langer K
    Int J Pharm; 2024 Sep; 662():124491. PubMed ID: 39032872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.